Insights From Mutational and Transcriptomic Profiles in Epithelial-myoepithelial Carcinoma
Authors:
- Ziyad AlsugairZAZiyad Alsugair
- Françoise DescotesFDFrançoise Descotes
- Anne ChampagnacACAnne Champagnac
- Jonathan LopezJLJonathan Lopez
- Maxime FieuxMFMaxime Fieux
- Pierre PhilousePPPierre Philouse
- Philippe CérusePCPhilippe Céruse
- Brice Eng ThamphyaBTBrice Eng Thamphya
- Daniel PissalouxDPDaniel Pissaloux
- Franck TirodeFTFranck Tirode
- Nazim BenzerdjebNBNazim Benzerdjeb
Open Access
- 25 March 2026
- journal article
- research article
- Published by Wolters Kluwer Health in American Journal of Surgical Pathology
- Vol. 50 (7) , 716-725
Abstract
Epithelial-myoepithelial carcinoma (EMC) is a rare malignant tumor of the salivary glands, often characterized by HRAS mutations. The present study aimed to better define the molecular and transcriptomic landscape of EMC and explore its relationship with other head and neck neoplasms, particularly basal cell adenoma (BCA). We retrospectively analyzed 14 EMC cases using histology, immunohistochemistry, and whole-exome capture RNA sequencing. HRAS mutations were identified in 57.0% (8/14) of EMC, predominantly at p.Gly61Arg. Additional mutations identified included PIK3CA , STAT5B , and NOTCH1 , as well as gene fusions such as HMGA2 :: WIF1 and FBXO32 :: PLAG1 . A comparative analysis with 54 RAS -mutated head and neck tumors revealed that HRAS mutations were not exclusive to EMC, as they were also found in benign entities such as BCAs. Transcriptomic profiling found that EMC and BCA shared significant gene expression similarities, clustering closely. Differential expression analysis found upregulation of GATA3 , CHI3L1 , GRIA2 , and MME in EMC, while BCAs had enrichment of Wnt-beta-catenin signaling. In contrast, EMCs had activation of the Ras-Raf-MAPK and PI3K-Akt pathways, supported by upregulation of E2F and G2-M checkpoint targets. Immunohistochemistry confirmed GATA3 positivity in HRAS -mutated EMCs. The frequent RAS mutations and overlapping transcriptomic profiles raise important diagnostic considerations and highlight the need for integrated molecular analyses to differentiate these entities. The EMCs displayed a recurrent HRAS mutation, also observed in other head and neck tumors, and were partially clustered with the cases of BCA, suggesting potential biological similarities.Keywords
This publication has 42 references indexed in Scilit:
- Malignant Transformation in Pleomorphic Adenoma: The Impact of DNA Methylation Profiling and Pathogenic MutationsLaboratory Investigation, 2025
- DNA Methylation Profiling of Salivary Gland Tumors Supports and Expands Conventional ClassificationLaboratory Investigation, 2024
- A Subset of Salivary Intercalated Duct Lesions Harbors Recurrent CTNNB1 and HRAS Mutations: A Molecular Link to Basal Cell Adenoma and Epithelial-Myoepithelial Carcinoma?Head and Neck Pathology, 2022
- Wholistic approach: Transcriptomic analysis and beyond using archival material for molecular diagnosisGenes, Chromosomes and Cancer, 2022
- SOX10 and GATA3 in Adenoid Cystic Carcinoma and Polymorphous AdenocarcinomaHead and Neck Pathology, 2019
- RAS Proteins and Their Regulators in Human DiseaseCell, 2017
- The Molecular Signatures Database Hallmark Gene Set CollectionCell Systems, 2015
- HRAS Mutations in Epithelial–Myoepithelial CarcinomaHead and Neck Pathology, 2013
- GATA3 Immunohistochemical Expression in Salivary Gland NeoplasmsHead and Neck Pathology, 2013
- EWSR1‐ATF1 fusion is a novel and consistent finding in hyalinizing clear‐cell carcinoma of salivary glandGenes, Chromosomes and Cancer, 2011